Mutual of America Capital Management LLC Cuts Stock Position in Vericel Co. (NASDAQ:VCEL)

Mutual of America Capital Management LLC cut its position in Vericel Co. (NASDAQ:VCEL) by 2.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 134,999 shares of the biotechnology company’s stock after selling 2,985 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.28% of Vericel worth $6,194,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of VCEL. Charles Schwab Investment Management Inc. lifted its holdings in shares of Vericel by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 410,390 shares of the biotechnology company’s stock valued at $14,614,000 after purchasing an additional 8,291 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Vericel by 14.2% in the fourth quarter. BNP Paribas Financial Markets now owns 55,964 shares of the biotechnology company’s stock valued at $1,993,000 after buying an additional 6,968 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Vericel by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 730,426 shares of the biotechnology company’s stock worth $26,011,000 after acquiring an additional 8,080 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Vericel during the fourth quarter worth about $566,000. Finally, Trexquant Investment LP increased its holdings in shares of Vericel by 1.8% during the fourth quarter. Trexquant Investment LP now owns 43,882 shares of the biotechnology company’s stock valued at $1,563,000 after acquiring an additional 763 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. TD Cowen lifted their target price on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Canaccord Genuity Group initiated coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price objective on the stock. BTIG Research cut their target price on Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, July 15th. Truist Financial lifted their price target on Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Finally, Stephens increased their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and a consensus target price of $55.75.

Vericel Stock Down 3.0 %

Shares of VCEL opened at $46.57 on Friday. The stock’s 50-day moving average price is $48.29 and its 200-day moving average price is $47.39. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -4,657.00 and a beta of 1.67. Vericel Co. has a 52 week low of $30.18 and a 52 week high of $54.10.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The business had revenue of $52.70 million for the quarter, compared to analysts’ expectations of $52.59 million. During the same quarter last year, the company earned ($0.11) EPS. The business’s revenue was up 14.8% on a year-over-year basis. As a group, equities analysts anticipate that Vericel Co. will post 0.12 EPS for the current fiscal year.

Insider Buying and Selling at Vericel

In other news, insider Sean C. Flynn sold 1,474 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $45.84, for a total transaction of $67,568.16. Following the sale, the insider now directly owns 487 shares of the company’s stock, valued at approximately $22,324.08. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $52.18, for a total value of $782,700.00. Following the completion of the sale, the insider now owns 707 shares of the company’s stock, valued at approximately $36,891.26. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sean C. Flynn sold 1,474 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $45.84, for a total transaction of $67,568.16. Following the transaction, the insider now owns 487 shares of the company’s stock, valued at $22,324.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,519 shares of company stock valued at $2,024,293. Corporate insiders own 5.20% of the company’s stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.